Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
92118-27-9
Molecular formula
C9H19ClN3O5P
Molecular weight
315.69 g/mol
Drug class
Nitrosourea alkylating antineoplastic agent
Mechanism of action
Generates reactive alkylating intermediates that form DNA crosslinks and interfere with DNA replication and transcription, causing tumour-cell death.
Indications / reported uses
Treatment of selected malignant melanoma and primary brain tumours, including glioblastoma, in countries where fotemustine is authorised; clinical use and approved lines of therapy are jurisdiction-specific
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Fotemustine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fotemustine Permitted Daily Exposure (PDE) report (the Fotemustine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fotemustine Occupational Exposure Limit (OEL) report (the Fotemustine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.